Company registration number 00946600 (England and Wales)
ESSENTIA PROTEIN SOLUTIONS LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
ESSENTIA PROTEIN SOLUTIONS LIMITED
COMPANY INFORMATION
Directors
Mr G L Whiley
Mr T G Cooke
Mr R Parnell
Mr A Jacobsen
Mr T U Hansen
(Appointed 20 March 2024)
Secretary
Mrs R Bristow-McGhee
Company number
00946600
Registered office
Units 10 + 11 Ramsay Road
Barnfield Industrial Estate
Tipton
West Mids
United Kingdom
DY4 9DU
Auditor
Xeinadin Audit Limited
100 Barbirolli Square
Manchester
Greater Manchester
United Kingdom
M2 3BD
ESSENTIA PROTEIN SOLUTIONS LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3 - 4
Independent auditor's report
5 - 7
Statement of comprehensive income
8
Balance sheet
9
Statement of changes in equity
10
Notes to the financial statements
11 - 22
ESSENTIA PROTEIN SOLUTIONS LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The directors present the strategic report for the year ended 31 December 2024.

Review of the business

Turnover decreased by £2,540,676 for the year ended 31/12/2024 to give a total of £18,284,914 compared to £20,825,590 for the previous period. The pre-tax profit for the year is £2,779,414 – an increase of £1,058,358 year on year, net margins have increased to 15.2%.

After the sharp increases in pork rind price during 2023, the market softened, and the raw material price eased into 2024. The gelatine industry are still sitting on high stocks of raw material and finished product. Rind supply and availability are currently stable.

Beef meat pricing has increased significantly over the last quarter. Demand is high and the overall cattle herd number and kill is down leading to record farmgate prices.

Foot and Mouth Disease (FMD) in Germany and Hungary has not affected the UK business unduly. None of the raw material that is processed at the Tipton site originates from either of these areas and any incoming Products of Animal Origin (POAO) from our sister sites is heat treated and therefore cleared for import and export.

Although inflation has come down slightly in 2024, the cost of living still remains high and Employers National Insurance contributions increase from April. We are proud to continue with our membership of the Living Wage Foundation.

The forecast for 2025 is to grow the business by 2% volume.

There have been no events since the balance sheet date which materially affect the position of the Company.

Principal risks and uncertainties

Raw material prices have remained relatively stable for the first part of 2025. ASF is a possible threat to the UK and Irish Pork industry although thankfully the virus remains clear of our shores. The total Pig kill in UK and Europe increased very slightly in the past 12 months and we have sufficient stock levels to mitigate any temporary shortages.

 

The company’s credit risk is primarily attributable to its trade debtors. Credit risk is managed, and minimised, by trading within agreed insured credit limits and continually monitoring payments against contractual agreements.

Development and performance

Essentia’s Mission is dedicated to building a better business for our customers. Continuous leadership training is undertaken to underpin our Culture and values with respect to meeting our Vision to fulfil customer needs. Essentia’s strategy is to be truly customer centric.

Corporate Social Responsibility with our stakeholders remains a top priority. SEDEX membership retained until December 2025.

Key performance indicators

Management use a range of performance measures to monitor and manage the business.

The key measures are:

ESSENTIA PROTEIN SOLUTIONS LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -

On behalf of the board

Mr T G Cooke
Director
25 September 2025
ESSENTIA PROTEIN SOLUTIONS LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -

The directors present their annual report and financial statements for the year ended 31 December 2024.

Principal activities
Results and dividends

A final dividend of £2.00 per share (2023 - £3.00 per share) was paid on 20 March 2024 in respect of the year ended 31 December 2023.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr G L Whiley
Mr T G Cooke
Mr V Hald-Christensen
(Resigned 20 March 2024)
Mr R Parnell
Mr A Jacobsen
Mr T U Hansen
(Appointed 20 March 2024)
Qualifying third party indemnity provisions

The company has made qualifying third party indemnity provisions for the benefit of its directors during the year. These provisions remain in force at the reporting date.

Auditor

The auditor, Xeinadin Audit Limited, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Strategic report

The Group has chosen, in accordance with Section 414 C(ii) of the Companies Act 2006, and as noted in this Directors' Report, to include certain matters in its Strategic Report that would otherwise be required to disclose in this Directors' Report, specifically in respect of the review of the business, disabled employees, research and development, future developments and key risks in the business.

ESSENTIA PROTEIN SOLUTIONS LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

Medium-sized companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.

On behalf of the board
Mr T G Cooke
Director
25 September 2025
ESSENTIA PROTEIN SOLUTIONS LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ESSENTIA PROTEIN SOLUTIONS LIMITED
- 5 -
Opinion

We have audited the financial statements of Essentia Protein Solutions Limited (the 'company') for the year ended 31 December 2024 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

ESSENTIA PROTEIN SOLUTIONS LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ESSENTIA PROTEIN SOLUTIONS LIMITED (CONTINUED)
- 6 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities including fraud and non-compliance with laws and regulations we have considered the following:

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas: timing of recognition of income, management override and stock valuation. In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override.

ESSENTIA PROTEIN SOLUTIONS LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF ESSENTIA PROTEIN SOLUTIONS LIMITED (CONTINUED)
- 7 -

We also obtained an understanding of the legal and regulatory frameworks that the company operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The key laws and regulations we considered in this context included UK Companies Act, employment law, health and safety, pensions legislation and tax legislation.

 

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which may be fundamental to the company's ability to operate or to avoid a material penalty

Audit response to risks identified

Our procedures to respond to risks identified included the following:

 

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members including internal specialists, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity's controls, and the nature, timing and extent of the audit procedures performed. Irregularities that result from fraud might be inherently more difficult to detect than irregularities that result from error. As explained above, there is an unavoidable risk that material misstatements may not be detected, even though the audit has been planned and performed in accordance with ISAs (UK).

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Michael Butt FCCA ACCA (Senior Statutory Auditor)
For and on behalf of Xeinadin Audit Limited, Statutory Auditor
Chartered Accountants
100 Barbirolli Square
Manchester
Greater Manchester
M2 3BD
United Kingdom
25 September 2025
ESSENTIA PROTEIN SOLUTIONS LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
2024
2023
Notes
£
£
Turnover
3
18,284,914
20,825,590
Cost of sales
(13,227,475)
(16,928,772)
Gross profit
5,057,439
3,896,818
Distribution costs
(1,049,403)
(944,775)
Administrative expenses
(1,119,980)
(1,002,776)
Other operating income
1,800
-
0
Operating profit
4
2,889,856
1,949,267
Interest receivable and similar income
7
39,893
2,868
Interest payable and similar expenses
8
(150,335)
(231,079)
Profit before taxation
2,779,414
1,721,056
Tax on profit
9
(742,027)
(452,549)
Profit for the financial year
2,037,387
1,268,507

The profit and loss account has been prepared on the basis that all operations are continuing operations.

ESSENTIA PROTEIN SOLUTIONS LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 9 -
2024
2023
Notes
£
£
£
£
Fixed assets
Intangible assets
11
-
0
1,534
Tangible assets
12
4,481,461
4,427,849
4,481,461
4,429,383
Current assets
Stocks
13
2,455,319
2,653,215
Debtors
14
3,357,930
3,569,716
Cash at bank and in hand
105,609
188,258
5,918,858
6,411,189
Creditors: amounts falling due within one year
15
(2,523,770)
(4,033,606)
Net current assets
3,395,088
2,377,583
Total assets less current liabilities
7,876,549
6,806,966
Provisions for liabilities
Deferred tax liability
16
889,745
857,549
(889,745)
(857,549)
Net assets
6,986,804
5,949,417
Capital and reserves
Called up share capital
18
500,000
500,000
Revaluation reserve
1,850,682
1,965,709
Profit and loss reserves
4,636,122
3,483,708
Total equity
6,986,804
5,949,417

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 25 September 2025 and are signed on its behalf by:
Mr T G Cooke
Director
Company registration number 00946600 (England and Wales)
ESSENTIA PROTEIN SOLUTIONS LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
Share capital
Revaluation reserve
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 January 2023
500,000
2,080,421
3,600,489
6,180,910
Year ended 31 December 2023:
Profit and total comprehensive income
-
-
1,268,507
1,268,507
Dividends
10
-
-
(1,500,000)
(1,500,000)
Transfers
-
(114,712)
114,712
-
Balance at 31 December 2023
500,000
1,965,709
3,483,708
5,949,417
Year ended 31 December 2024:
Profit and total comprehensive income
-
-
2,037,387
2,037,387
Dividends
10
-
-
(1,000,000)
(1,000,000)
Transfers
-
(115,027)
115,027
-
Balance at 31 December 2024
500,000
1,850,682
4,636,122
6,986,804
ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
1
Accounting policies
Company information

Essentia Protein Solutions Limited is a private company limited by shares incorporated in England and Wales. The registered office and principal place of business is Units 10 + 11 Ramsay Road, Barnfield Industrial Estate, Tipton, West Mids, United Kingdom, DY4 9DU.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention , as modified by the revaluation of land and buildings, and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland and the Companies Act 2006. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements LGI Denmark ApS as at 31 December 2024. These consolidated financial statements are available from its registered office, 33 Ulsnaes - DK 6300 Grasten, Denmark.

1.2
Turnover

Turnover represents sales to external customers at invoiced amounts less value added tax or local taxes on sales. Revenue is recognised when goods are shipped to the customer.

 

Turnover principally consists of the sale of animal protein solutions for the food and beverage industry.

1.3
Intangible fixed assets other than goodwill

Intangible assets are represented by Computer Software which is capitalised where there is a clearly defined project, related expenditure is separately identifiable and it has been assessed for technical and commercial viability.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
33% straight line

The carrying amounts of the company's assets are reviewed for impairment when events or changes in circumstances indicate that the carrying amount of the fixed asset may not be recoverable. If any such indication exists, the asset's recoverable amount is estimated and an impairment provision made if appropriate.

ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 12 -
1.4
Tangible fixed assets

Tangible fixed assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Land is not depreciated. Depreciation on other tangible fixed assets is charged to the profit or loss so as to write off their value, over their estimated useful lives, using the following methods:

Freehold land and buildings
5% straight line
Leasehold land and buildings
Over the term of the lease
Plant and equipment
6% - 33.33% straight line
Motor vehicles
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

At each reporting date, the Group reviews the carrying amounts of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any.

 

If the recoverable amount of an asset is estimated to be less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount. Impairment loss is recognised as an expense immediately.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Costs, which comprise direct production costs, are based on the method most appropriate to the type of inventory class, but usually on a first-in-first-out basis. Overheads are charged to profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 13 -
Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 14 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Retirement benefits

The obligations for contributions to defined contribution scheme are recognised as an expense as incurred. The assets of the scheme are held separately from those of the Company in an independent administered fund.

1.10
Leases
As lessee

Rentals paid under operating lease are charged to the SOCI on a straight line basis over the period of the lease.

1.11
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

1.12

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting. Dividends on shares recognised as liabilities are recognised as expenses and classified within interest payable.

1.13

Interest Income

Interest income is recognised in the SOCI using the effective interest method.

1.14

Provisions for liabilities

Provisions are made where an event has taken place that gives the company a legal or constructive obligation that probably requires settlement by transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.

 

Provisions are charged as an expense to the SOCI in the year that the company becomes aware of the obligation, and are measured at the best estimate at the Statement of Financial position date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.

 

When payments are eventually made, they are charge to the provision carried in the Statement of Financial position date.

ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 15 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Critical judgements

The following judgements (apart from those involving estimates) have had the most significant effect on amounts recognised in the financial statements.

Categorisation of leases

In categorising leases as finance leases or operating leases, management makes judgements as to whether significant risks and rewards of ownership have transferred to the Company as lessee.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Useful life of fixed assets

In making decisions regarding the depreciation of fixed assets, management must estimate the useful life of said assets to the business. A change in estimate would result in a change in the depreciation charged to the SOCI in each year.

3
Turnover and other revenue
2024
2023
£
£
Turnover analysed by class of business
Drinde
8,779,546
10,655,003
Beef
1,010,583
1,746,793
Stocks/broths
4,046,300
3,343,284
Other
2,750,878
2,792,461
Fat
1,486,099
2,176,440
Commissions
211,508
111,609
18,284,914
20,825,590
2024
2023
£
£
Turnover analysed by geographical market
United Kingdom
16,132,177
18,422,933
Europe
2,152,737
2,402,657
18,284,914
20,825,590
ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
3
Turnover and other revenue
(Continued)
- 16 -
2024
2023
£
£
Other revenue
Interest income
39,893
2,868
4
Operating profit
2024
2023
Operating profit for the year is stated after charging/(crediting):
£
£
Exchange losses/(gains)
2,456
(4,548)
Fees payable to the company's auditor for the audit of the company's financial statements
17,400
14,680
Depreciation of owned tangible fixed assets
349,425
317,199
Amortisation of intangible assets
1,534
6,150
Operating lease charges
70,102
66,095
5
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Management and administration
11
11
Sales
5
3
Manufacturing
31
31
Total
47
45

Their aggregate remuneration comprised:

2024
2023
£
£
Wages and salaries
2,173,428
2,122,104
Pension costs
287,518
247,611
2,460,946
2,369,715

Key management personnel include all directors and a number of senior managers across the company who together have authority and responsibility for planning, directing and controlling the activities of the company. The total compensation paid to key management personnel for services provided to the company was £610,332 (2023 - £633,170).

ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 17 -
6
Directors' remuneration
2024
2023
£
£
Remuneration for qualifying services
273,700
293,276
Company pension contributions to defined contribution schemes
27,868
25,785
301,568
319,061
Remuneration disclosed above include the following amounts paid to the highest paid director:
2024
2023
£
£
Remuneration for qualifying services
155,075
175,936
Company pension contributions to defined contribution schemes
15,948
14,756

In addition to the above, consultancy fees were paid to a director of the company amounting to £12,000 (2023: £12,000).

7
Interest receivable and similar income
2024
2023
£
£
Interest income
Interest on bank deposits
351
463
Other interest income
39,542
2,405
Total income
39,893
2,868
8
Interest payable and similar expenses
2024
2023
£
£
Interest payable to group undertakings
145,146
225,795
Other interest on financial liabilities
5,189
5,284
150,335
231,079
9
Taxation
2024
2023
£
£
Current tax
UK corporation tax on profits for the current period
709,831
417,759
ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
9
Taxation
2024
2023
£
£
(Continued)
- 18 -
Deferred tax
Origination and reversal of timing differences
32,196
34,790
Total tax charge
742,027
452,549

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Profit before taxation
2,779,414
1,721,056
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.52%)
694,854
404,792
Tax effect of expenses that are not deductible in determining taxable profit
2,941
4,208
Effect of change in corporation tax rate
-
0
9
Permanent capital allowances in excess of depreciation
12,036
8,750
Deferred tax adjustment
32,196
34,790
Taxation charge for the year
742,027
452,549
10
Dividends
2024
2023
£
£
Final paid
1,000,000
1,500,000
ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 19 -
11
Intangible fixed assets
Software
£
Cost
At 1 January 2024
233,194
Disposals
(116,995)
At 31 December 2024
116,199
Amortisation and impairment
At 1 January 2024
231,660
Amortisation charged for the year
1,534
Disposals
(116,995)
At 31 December 2024
116,199
Carrying amount
At 31 December 2024
-
0
At 31 December 2023
1,534
12
Tangible fixed assets
Freehold land and buildings
Leasehold land and buildings
Plant and equipment
Motor vehicles
Total
£
£
£
£
£
Cost or valuation
At 1 January 2024
6,019,587
96,334
4,844,032
8,915
10,968,868
Additions
142,903
-
0
260,134
-
0
403,037
Disposals
-
0
-
0
(66,424)
-
0
(66,424)
At 31 December 2024
6,162,490
96,334
5,037,742
8,915
11,305,481
Depreciation and impairment
At 1 January 2024
2,416,014
96,334
4,024,365
4,306
6,541,019
Depreciation charged in the year
184,230
-
0
163,406
1,789
349,425
Eliminated in respect of disposals
-
0
-
0
(66,424)
-
0
(66,424)
At 31 December 2024
2,600,244
96,334
4,121,347
6,095
6,824,020
Carrying amount
At 31 December 2024
3,562,246
-
0
916,395
2,820
4,481,461
At 31 December 2023
3,603,573
-
0
819,667
4,609
4,427,849
ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
12
Tangible fixed assets
(Continued)
- 20 -

Included in cost or valuation of land and buildings is freehold land of £684,181 (2023 - £684,181) which is not depreciated.

 

Freehold land and property was revalued to fair value in April 2022 based on a valuation undertaken by The Culshaw Partnership, chartered surveyors.

 

The directors believe that the carrying value of land and buildings at year end is a fair reflection of the asset's value at year end.

Freehold property
2024
2023
£
£
Cost
3,388,595
3,388,595
Accumulated depreciation
(2,370,505)
(2,301,302)
Carrying value
1,018,090
1,087,293
13
Stocks
2024
2023
£
£
Raw materials and consumables
115,647
91,892
Finished goods and goods for resale
2,339,672
2,561,323
2,455,319
2,653,215
14
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
3,191,254
3,450,899
Corporation tax recoverable
39,656
-
0
Amounts owed by group undertakings
1,265
989
Other debtors
52,596
46,874
Prepayments and accrued income
73,159
70,954
3,357,930
3,569,716
ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 21 -
15
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
403,082
345,608
Amounts owed to group undertakings
1,728,636
3,314,231
Corporation tax
-
0
233
Other taxation and social security
54,629
52,283
Accruals and deferred income
337,423
321,251
2,523,770
4,033,606
16
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the company and movements thereon:

Liabilities
Liabilities
2024
2023
Balances:
£
£
Accelerated capital allowances
196,271
164,075
Revaluations
693,474
693,474
889,745
857,549
2024
Movements in the year:
£
Liability at 1 January 2024
857,549
Charge to profit or loss
32,196
Liability at 31 December 2024
889,745
17
Retirement benefit schemes
2024
2023
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
287,518
247,611

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

Contributions amounting to £2,370 (2023 - £2,236), were payable to the fund and are included in creditors.

ESSENTIA PROTEIN SOLUTIONS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 22 -
18
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
500,000
500,000
500,000
500,000
19
Operating lease commitments
As lessee

Minimum lease payments under non-cancellable operating leases fall due as follows:

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

2024
2023
£
£
Within 1 year
106,176
99,660
Years 2-5
161,692
135,094
267,868
234,754
20
Directors' transactions

Consultancy fees were paid to G Whiley in the year amounting to £12,000 (2023: £12,000).

21
Ultimate Controlling Party

The parent company of the largest and smallest group that includes the company and for which group financial statements are prepared is LGI Denmark Aps. Copies of these financial statements can be obtained from the registered office at 33 Ulsnaes - DK 6300 Gratsen, Denmark.

 

The ultimate holding company is Laurisden Group Inc, which is a company incorporated in the United States of America.

2024-12-312024-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr G L WhileyMr T G CookeMr V Hald-ChristensenMr R ParnellMr A JacobsenMr T U HansenMrs R Bristow-McGhee009466002024-01-012024-12-3100946600bus:Director12024-01-012024-12-3100946600bus:Director22024-01-012024-12-3100946600bus:Director42024-01-012024-12-3100946600bus:Director52024-01-012024-12-3100946600bus:Director62024-01-012024-12-3100946600bus:CompanySecretary12024-01-012024-12-3100946600bus:Director32024-01-012024-12-3100946600bus:RegisteredOffice2024-01-012024-12-31009466002024-12-31009466002023-01-012023-12-3100946600core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3100946600core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3100946600core:IntangibleAssetsOtherThanGoodwill2024-12-3100946600core:IntangibleAssetsOtherThanGoodwill2023-12-3100946600core:ComputerSoftware2024-12-3100946600core:ComputerSoftware2023-12-31009466002023-12-3100946600core:LandBuildingscore:OwnedOrFreeholdAssets2024-12-3100946600core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3100946600core:PlantMachinery2024-12-3100946600core:MotorVehicles2024-12-3100946600core:LandBuildingscore:OwnedOrFreeholdAssets2023-12-3100946600core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3100946600core:PlantMachinery2023-12-3100946600core:MotorVehicles2023-12-3100946600core:ShareCapital2024-12-3100946600core:ShareCapital2023-12-3100946600core:RevaluationReserve2024-12-3100946600core:RevaluationReserve2023-12-3100946600core:RetainedEarningsAccumulatedLosses2024-12-3100946600core:RetainedEarningsAccumulatedLosses2023-12-3100946600core:ShareCapital2022-12-3100946600core:RevaluationReserve2022-12-3100946600core:RetainedEarningsAccumulatedLosses2022-12-3100946600core:ShareCapitalOrdinaryShareClass12024-12-3100946600core:ShareCapitalOrdinaryShareClass12023-12-3100946600core:RevaluationReserve2023-01-012023-12-3100946600core:RevaluationReserve2024-01-012024-12-3100946600core:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3100946600core:ComputerSoftware2024-01-012024-12-3100946600core:LandBuildingscore:OwnedOrFreeholdAssets2024-01-012024-12-3100946600core:LandBuildingscore:LongLeaseholdAssets2024-01-012024-12-3100946600core:PlantMachinery2024-01-012024-12-3100946600core:MotorVehicles2024-01-012024-12-3100946600core:UKTax2024-01-012024-12-3100946600core:UKTax2023-01-012023-12-310094660012024-01-012024-12-310094660012023-01-012023-12-3100946600core:ComputerSoftware2023-12-3100946600core:LandBuildingscore:OwnedOrFreeholdAssets2023-12-3100946600core:LandBuildingscore:LeasedAssetsHeldAsLessee2023-12-3100946600core:PlantMachinery2023-12-3100946600core:MotorVehicles2023-12-31009466002023-12-3100946600core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-01-012024-12-3100946600core:CurrentFinancialInstruments2024-12-3100946600core:CurrentFinancialInstruments2023-12-3100946600bus:OrdinaryShareClass12024-01-012024-12-3100946600bus:OrdinaryShareClass12024-12-3100946600bus:OrdinaryShareClass12023-12-3100946600core:WithinOneYear2024-12-3100946600core:BetweenTwoFiveYears2024-12-3100946600bus:PrivateLimitedCompanyLtd2024-01-012024-12-3100946600bus:FRS1022024-01-012024-12-3100946600bus:Audited2024-01-012024-12-3100946600bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP